pre-IPO PHARMA

COMPANY OVERVIEW

Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties.


LOCATION

  • La Jolla, CA, USA

  • THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Metabolic Disorders
  • Oncology

  • WEBSITE

    https://ambrx.com/


    CAREER WEBSITE

    https://ambrx.com/careers/


    SOCIAL MEDIA


    INVESTORS

    everbright fosun-pharma hopu wuxi-pharmatech


    PRESS RELEASES


    Jun 30, 2021

    Ambrx Appoints Sonja Nelson as Chief Financial Officer


    Jun 17, 2021

    Ambrx Announces Pricing of Initial Public Offering


    Jun 10, 2021

    Ambrx Announces Formation and Members of Scientific Advisory Board


    Apr 14, 2021

    Ambrx Appoints Olivia Ware and Katrin Rupalla to its Board of Directors


    Mar 17, 2021

    Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer


    For More Press Releases


    Google Analytics Alternative